Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Poorly Differentiated Malignant Neuroendocrine Carcinoma”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Early research (Phase 1)Active Not RecruitingNCT04514497
What this trial is testing

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Who this might be right for
Metastatic Lung Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Neuroendocrine Carcinoma+9 more
National Cancer Institute (NCI) 29
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Not applicableStudy completedNCT00899496
What this trial is testing

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

Who this might be right for
Cancer
Wake Forest University Health Sciences 54
Very early researchEnded earlyNCT00499733
What this trial is testing

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT04759911
What this trial is testing

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Who this might be right for
Malignant Thyroid Gland NeoplasmPoorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland Carcinoma+4 more
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT02113800
What this trial is testing

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Who this might be right for
Poorly Differentiated Malignant Neuroendocrine CarcinomaNeuroendocrine Carcinoma, Grade 3Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3+2 more
AIO-Studien-gGmbH
Not applicableWithdrawnNCT00378781
What this trial is testing

Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

Who this might be right for
Cancer
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
40